
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>News &amp; Press</title>
<link>https://gada.site-ym.com/news/default.asp</link>
<description><![CDATA[  Read about recent events, essential information and the latest community news.  ]]></description>
<lastBuildDate>Fri, 5 Jun 2026 11:20:06 GMT</lastBuildDate>
<pubDate>Wed, 31 May 2023 04:00:00 GMT</pubDate>
<copyright>Copyright &#xA9; 2023 Generic Animal Drug Alliance</copyright>
<atom:link href="https://gada.site-ym.com/news/news_rss.asp?cat=17622" rel="self" type="application/rss+xml"></atom:link>
<item>
<title>Animal Drug GMP Inspections Now Under FDA-EU MRA Scope</title>
<link>https://gada.site-ym.com/news/news.asp?id=641796</link>
<guid>https://gada.site-ym.com/news/news.asp?id=641796</guid>
<description><![CDATA[<span style="color: #000000; font-size: 14px; font-family: Arial;">The U.S.-EU Mutual Recognition Agreement (MRA) Sectoral Annex for Pharmaceutical Good Manufacturing Practices (GMP) has been expanded to include inspections of animal drugs. By utilizing each other’s inspection reports and related information, the MRA enables the FDA and the EU to avoid duplication of some animal drug inspections. READ MORE:&nbsp;<span style="color: #1f497d; font-size: 11pt; font-family: Calibri, sans-serif;"><a href="https://www.fda.gov/animal-veterinary/cvm-updates/fda-and-european-union-announce-mutual-recognition-agreement-pharmaceutical-good-manufacturing?utm_medium=email&amp;utm_source=govdelivery" target="_blank">https://www.fda.gov/animal-veterinary/cvm-updates/fda-and-european-union-announce-mutual-recognition-agreement-pharmaceutical-good-manufacturing?utm_medium=email&amp;utm_source=govdelivery</a></span></span>]]></description>
<pubDate>Wed, 31 May 2023 05:00:00 GMT</pubDate>
</item>
<item>
<title>GADA Supports FDA Restructuring; CVM to Remain Stand-Alone Center</title>
<link>https://gada.site-ym.com/news/news.asp?id=639418</link>
<guid>https://gada.site-ym.com/news/news.asp?id=639418</guid>
<description><![CDATA[<span style="color: #333333; font-family: Arial; font-size: 14px; background-color: #ffffff;">GADA supports the FDA restructuring announced by Commissioner Robert Califf on January 31, 2023, which creates a Human Foods Program while maintaining the Center for Veterinary Medicine (CVM) as a stand-alone center. Relevant food safety activities will be coordinated between CVM and the newly created Human Foods Program. “The restructuring announced by Commissioner Califf emphasizes the importance of the responsibilities of the Center for Veterinary Medicine to not only animal health, but human health as well,” said GADA Chair Stephanie Batliner. “Animal medications approved by CVM are used to treat both companion animals and food animals. GADA Member organizations look forward to continued interaction with CVM as we work to bring more affordable medications to market.”</span>]]></description>
<pubDate>Mon, 20 Feb 2023 15:40:00 GMT</pubDate>
</item>
<item>
<title>FDA Warns About Risk of Xylazine Exposure in Humans</title>
<link>https://gada.site-ym.com/news/news.asp?id=639422</link>
<guid>https://gada.site-ym.com/news/news.asp?id=639422</guid>
<description><![CDATA[<span style="font-family: Arial;"><span style="font-size: 14px; background-color: #ffffff; font-family: Arial; color: #333333;">The FDA is communicating to health care professionals about serious risks associated with xylazine exposure in humans. FDA is aware that xylazine is increasingly detected in the illicit drug supply and in drug overdoses. Xylazine is an FDA-approved animal drug used as a sedative and analgesic in veterinary medicine, but is not approved for use in humans. The FDA has issued an&nbsp;</span><span style="font-size: 14px; color: #000000;"><a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-professionals-risks-patients-exposed-xylazine-illicit-drugs" target="_blank">Alert</a></span><span style="font-size: 14px; background-color: #ffffff; color: #333333;">&nbsp;and a&nbsp;</span><span style="font-size: 14px; color: #000000;"><a href="https://www.fda.gov/media/162981/download" target="_blank">letter to stakeholders</a></span><span style="font-size: 14px; background-color: #ffffff; color: #333333;">&nbsp;to communicate the risks and considerations for management.</span></span>]]></description>
<pubDate>Tue, 8 Nov 2022 15:41:00 GMT</pubDate>
</item>
</channel>
</rss>
